Rising Biosciences
Launches RBS0346 Clinical Strength
Dulcis Stem Cell Cream on
Amazon; Advancements in FDA Approvals Indicate
Bright Future for Cannophen
Sandusky, OH -- July
2, 2018
-- InvestorsHub NewsWire -- Rising Biosciences, Inc.
(RBII) ("RBII" "the Company"), a
research and development company focusing on oral and topical
pharmaceuticals with strict standards set forward by the
pharmaceutical compounding industry, is pleased to announce
that its revolutionary RBS0346 Clinical Strength
Dulcis Stem Cell Cream will be available on Amazon.com in
the coming days.
This marks the Company's
second product on Amazon's virtual shelves so far this year.
"Our RBS0238
Clinical Strength Peptide Complex hit the Top Ten in its
category only days after launch and exceeded our own
expectations as we sold out in the first week before quickly
replenishing our inventory. We are confident the Stem
Cell Cream will follow suit in exceeding expectations
and are well
prepared with inventory accordingly," states CEO Robert
Weber.
The Company has also
reached advanced negotiations to contract with
Producers/Processors in MMJ States to License and Market
Cannophen
and
other THC products.
"These
relationships
can have an
enormous impact on revenues for our company and
shareholders," states Weber. "We are confident that we'll have
strategic alliances and partnerships in place to effect RBII
products on dispensary shelves by the end of Q3 2018."
"Last week, the FDA recently
approved the use of an oral
cannabidiol (CBD) solution called Epidiolex
for the
treatment of two rare forms of
epilepsy: LennoxGastaut syndrome and
Dravet
syndrome,
in patients
aged 2 and older. It's the first time the
regulatory body had greenlit
a medication
based on natural not synthesized CBD, and some experts are hailing
this approval as a major step forward for the medical cannabis
industry."
"We see this as a tipping
point,"
says COO
Arthur Hall. "It rapidly
destigmatizes
what cannabis
can do.
It is a monumental step in terms
of overall regulatory climate shifts and indicative of future
opportunities for a company like Rising
Biosciences."
There are now 30 states
with some kind of legalized marijuana provision in place. Oklahoma
became the latest state to legalize MMJ and there are other proposals
to fully legalize the drug at the federal level, including one by
New Jersey Sen. Cory Booker, an oft-mentioned potential 2020
presidential candidate.
Weber
concludes: "We will
continue an assertive approach here in line with legally available
channels as we continue to identify revolutionary formulas and
applications while ensuring distribution
outlets all the while."
$RSII on Twitter for LIVE
company updates! www.twitter.com/risingindiausa
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act
of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934,
and are subject to the safe harbor created by those rules. All
statements, other than statements of fact, included in this
release, including, without limitation, statements regarding
potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward- looking statements to reflect events or circumstances
after the date of this release.
CONTACT
INFO: For Investor
Inquiries: IR@risingbiosciences.com
